[Iontophoresis assisted corneal crosslinking]
Cantero Muñoz P, Maceira Rozas MC
Record ID 32016001102
Spanish
Authors' objectives:
Objective: assess the clinical effectiveness and safety of I-CXL as a therapeutic technique in the treatment of corneal ectasias and other corneal diseases.
Authors' recommendations:
Conclusions: in the databases analysed in this review, I-CXL is judged to be capable of stabilising and/or reducing the progression of KC, with its efficacy being lower than that of classic CXL. It is considered to be a low-risk procedure, and most of the complications are transient and of scant severity. These outcomes must be interpreted with caution, since the existing evidence is very limited both in quantity and quality, and is based on some 200 patients treated worldwide. In the absence of comparative quality studies (CXL vs I-CXL) and in view of the uncertainty surrounding its long-term efficacy and safety, I-CXL cannot be said to improve
on the outcomes of the classical technique.
Details
Project Status:
Completed
URL for project:
https://avalia-t.sergas.gal/Paxinas/web.aspx?tipo=paxtxt&idLista=4&idContido=688&migtab=38%3b39%3b688&idTax=12028
Year Published:
2016
URL for published report:
http://avalia-t.sergas.es/DXerais/687/CT201603CrosslinkingDEF.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Humans
- Cornea
- Iontophoresis
- Keratoconus
Contact
Organisation Name:
Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
Contact Address:
Conselleria de Sanidade, Xunta de Galicia, San Lazaro s/n 15781 Santiago de Compostela, Spain. Tel: 34 981 541831; Fax: 34 981 542854;
Contact Name:
avalia-t@sergas.es
Contact Email:
avalia-t@sergas.es
Copyright:
Scientific and Technical Advice Unit, avalia-t
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.